Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mechanisms of Resistance to Antibody–Drug Conjugates

Cancers(2023)10.3390/cancers15041278Source: DataRank Database

Mechanisms of Resistance to Antibody–Drug Conjugates is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0. It has been cited 140 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access140 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 16.67)OA: goldTopics (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Bogang Wu ORCID,Laura M. Spring ORCID,Leif W. Ellisen ORCID,Aditya Bardia ORCID,Rachel O. Abelman ORCID

Live enrichment

PubMed:36831621 PMC:PMC9954407 OpenAlex:https://openalex.org/W4321251998

NCI R01

Grant: T32CA071345

NRSA T32

Grant: 5R01C1260890

NIH HHS

Grant: T32, T32CA071345

NCI NIH HHS

Grant: R01 CA260890

National Institutes of Health

Grant: 5T32CA071345-08

Training Program in Cancer Biology

FWCI

16.67

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/15/4/1278/pdf?version=1676616583

publisherhttps://www.mdpi.com/2072-6694/15/4/1278/pdf?version=1676616583

journalhttps://doi.org/10.3390/cancers15041278

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36831621

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9954407

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research03 medical and health sciences0302 clinical medicine

Keywords

MedicineBreast cancerAntibody-drug conjugateDrug resistanceTriple-negative breast cancerDrugAntibodyAntigenCancerChemotherapyCancer researchOncologyPharmacologyImmunologyMonoclonal antibodyInternal medicineBiologyTargeted TherapiesAntibody–drug ConjugatesReview

Sustainable Development Goals

SDG 0: Good health and well-being